{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment *6153*

Activity Steps

Description

Cognate Code 6153

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Discuss the complex surgical procedures and novel therapeutics that have emerged as standard of care for epithelial ovarian cancer.
  2. List targeted therapies that represent alternatives to traditional surgical therapy.
  3. Outline the role of antiangiogenics and poly (ADP-ribose) polymerase inhibitors in improving progression-free survival.
  4. Guide patients in obtaining appropriate germline genetic testing.
  5. Assist patients with epithelial ovarian cancer in selecting optimal therapy.
Price: $25.00

Credits:

  • ACOG 2.0 CME

The American College of Obstetricians and Gynecologists is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credit(s) The American College of Obstetricians and Gynecologists designates this journal-based activity for a maximum of 2 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

College Cognate Credit(s) The American College of Obstetricians and Gynecologists designates this journal-based activity for a maximum of 2 Category 1 College Cognate Credits. The College has a reciprocity agreement with the AMA that allows AMA PRA Category 1 Credits TM to be equivalent to College Cognate Credits.

Professions: Physician
Test Code: ONG1220A
Published: December 3, 2020
Expires: 1/31/2023
Required Passing Score: 7/9 (77%)
Authors: Katherine C. Kurnit, MD, MPH, Gini F. Fleming, MD, and Ernst Lengyel, MD, PhD
Specialties: OB/GYN